1336: Dialysis | Skeptical Sunday

What It Covers

Jordan Harbinger and researcher Jessica Wynne examine the U.S. dialysis industry, where 800,000 Americans with kidney failure depend on a $50 billion system controlled by two companies. The episode covers treatment realities, profit-driven incentives that discourage transplants and home dialysis, systemic prevention failures, and the racial and economic disparities that funnel patients into permanent treatment.

Key Questions Answered

• •Survival statistics: Fewer than 40% of dialysis patients survive beyond five years, comparable to many cancer diagnoses. Infections cause 36% of all dialysis deaths, with sepsis mortality running 100–300 times higher than the general population. Approximately 21% of patients die after voluntarily stopping treatment, citing the burden of three-to-five-hour sessions three times weekly as unbearable.
• •Duopoly control: DaVita and Fresenius control roughly 70% of U.S. dialysis clinics, operating approximately 2,800 and 2,600 locations respectively. This near-duopoly creates a captive patient base that cannot shop around, enabling both companies to shape federal regulations through roughly $2 million each in annual lobbying and by funding patient advocacy groups that oppose industry reforms.
• •Financial incentive misalignment: Medicare pays approximately $90,000 annually per in-clinic dialysis patient but only $60,000 for home dialysis. A kidney transplant costs Medicare around $110,000 total, saving roughly $270,000 over ten years compared to continued dialysis. For-profit clinics therefore have direct financial incentives to keep chairs filled rather than transition patients to cheaper, more effective alternatives.
• •Transplant access disparity: Patients at for-profit dialysis clinics are 64% less likely to reach the kidney transplant waitlist compared to patients at nonprofit clinics, even after controlling for health status and demographics. A 2015 whistleblower lawsuit alleged DaVita systematically discouraged transplant referrals. The 90,000-person waitlist carries average wait times of three to five years, during which patients remain on billable dialysis.
• •Home dialysis underutilization: Only 12% of U.S. dialysis patients use home peritoneal dialysis, compared to 40% in the Netherlands and over 70% in Hong Kong. Home dialysis produces lower infection rates, greater scheduling flexibility, and better quality-of-life outcomes. Countries prioritizing home dialysis as the default option report lower mortality rates, demonstrating the gap is policy-driven rather than medically necessary.
• •Prevention economics: Diabetes and hypertension cause approximately 70% of kidney failure cases, both conditions that are manageable with early intervention. A blood test and urine test can detect chronic kidney disease early enough to slow or prevent progression. Medicare spends $36 billion annually on dialysis for under 1% of its population, yet there is no billing code for prevention, creating a system that profits from late-stage intervention rather than avoiding it.